Publications by authors named "Yueqiang Gao"
ACS Med Chem Lett
December 2016
Article Synopsis
- Current toxoplasmosis treatments focus on inhibiting dihydrofolate reductase (DHFR) in the parasite, with pyrimethamine being the most common but having toxic side effects due to similar binding sites in humans.
- Computational analysis led to the creation of TRC-19, a new inhibitor that shows significantly better potency (IC of 9 nM) and selectivity (89-fold) for the parasite's DHFR compared to human DHFR.
- Overall, 50% of the newly designed inhibitors met criteria for effectiveness, demonstrating the success of the structure-based drug design method employed in this research.
